hydrogen sulphide-releasing derivative of naproxen (ATB-346) - Antibe
https://www.businesswire.com/news/home/20200228005048/en/Antibe-Therapeutics-Announces-Enrollment-Patient-Phase-2B
 
Feb 28, 2020
 
Prev Next